|Articles|May 1, 2019
- Pharmaceutical Executive-05-01-2019
- Volume 39
- Issue 5
Pharmaceutical Executive, May 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive May 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 7 years ago
Impact Investing and R&Dabout 7 years ago
New Flare-Up in Europe's External Reference Pricing Debateabout 7 years ago
It’s Time for a Chief Adherence Officerabout 7 years ago
Adopting New Technology: Barriers and Breakthroughsabout 7 years ago
The CFO Evolutionabout 7 years ago
We’ve Got You Coveredabout 7 years ago
Survey Spotlights the CFO’s Strategic Riseabout 7 years ago
FDA After Gottlieb: Thorny Issues, Political Challengesabout 7 years ago
Easing the Path to Profitabilityabout 7 years ago
A Strategic Approach to Pharma R&D Portfolio PlanningAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata
2
Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio
3
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
4
Roche Enters $2.3 Billion Global Collaboration with Nurix Therapeutics to Co-Develop and Co-Commercialize Bexobrutideg
5